India Digital X-ray Market Assessment, By Product [Stationary Digital Radiology System, Portable Digital Radiology System], By Technology [Direct Digital Radiology, Computed Digital Radiology], By Application [Cardiovascular Imaging, Chest Imaging, Dental

India Digital X-ray Market Assessment, By Product [Stationary Digital Radiology System, Portable Digital Radiology System], By Technology [Direct Digital Radiology, Computed Digital Radiology], By Application [Cardiovascular Imaging, Chest Imaging, Dental Imaging, Digital Mammography, Orthopedic Imaging, Others], By End-user [Hospitals, Diagnostic Imaging Centers, Others], By Region, Opportunities and Forecast, FY2018-FY2032F

Global alopecia market is projected to witness a CAGR of 8.75% during the forecast period 2024-2031, growing from USD 9.52 billion in 2023 to USD 18.62 billion in 2031. The market for alopecia therapeutics is anticipated to thrive at a faster pace under the influence of the growing disease burden, robust research environment around the disease, rising awareness about alopecia, and strengthening the healthcare system.

Alopecia is an inflammatory autoimmune disease that causes nonscarring hair loss that can significantly impact both the physical and psychological well-being of patients. The intensity of hair loss may vary depending on the type of alopecia; alopecia areata is the most common type of alopecia in terms of prevalence. Drivers for this market include the increasing geriatric population, rising prevalence of alopecia and related conditions like Polycystic Ovary Syndrome (PCOS), growing awareness and demand for treatments, and advancements in therapies. Despite these driving forces, the market also faces some challenges, such as side effects associated with alopecia treatment, which hinder market growth. Additionally, robust research findings from potential pharmaceutical candidates further enhance futuristic market growth.

In July 2024, Dermaliq Therapeutics, Inc. announced statistically significant topline data from a clinical trial for its topical product candidate DLQ01 for male pattern baldness. The trial showed that DLQ01 increased target area hair counts by 12.3% from baseline, with 83% of subjects responding positively. Endpoints of the study included the changes from baseline at the end of the study at six months in target area hair counts, anagen to telogen ratios, and cutaneous safety. The trial was conducted at Sinclair Dermatology, Melbourne, Australia.

High Disease Burden of Alopecia to Boost Market Demand

The population affected by alopecia conditions is steadily growing, and thus, the demand for alopecia therapeutics is also rising swiftly. The high disease burden of alopecia not only underscores the urgent need for effective treatments but also stimulates market growth through increased prevalence, significant psychosocial impacts on patients, and a robust focus on research and development. These factors collectively enhance the therapeutic landscape for alopecia, promising a dynamic future for the market. The efforts made by stakeholders such as market players, research organizations, and associations to reduce the disease burden are further providing market growth. According to the data published by the National Alopecia Areata Foundation, approximately 2% of people worldwide will experience alopecia areata at some point in their lives. In the United States, nearly 7 million people and around 160 million people globally either have or will develop alopecia areata. Currently, about 700,000 people in the United States have some form of alopecia areata.

Novel Therapy Development to Propel Market Growth

The conventional treatment options for alopecia include pharmaceutical administration through oral and topical routes and platelet-rich plasma therapy. Novel therapies have evolved in recent times which hold promising growth for the market. Researchers across the globe are involved in various research models to explore the therapeutic potential of novel therapies to stimulate hair growth and reverse hair loss. One such example is demonstrated in an article published in Advanced Materials journals in April 2024; researchers have created a new treatment to reverse hair loss caused by the autoimmune disease alopecia areata. They used a microneedle patch to painlessly target affected areas of the skin. Alopecia areata leads to hair loss when T cells mistakenly attack hair follicles. To regain control over hyperactive immune cells, researchers from Brigham and Women’s Hospital and MIT delivered T cell regulators directly to the sites of hair loss to stop the autoimmune activity.

Alopecia Areata Segment to Dominate the Alopecia Market

The alopecia areata segment is poised to dominate the global alopecia market due to several key factors. As an autoimmune condition characterized by patchy hair loss, alopecia areata affects approximately a significant amount of the population. The immune response does not permanently damage hair follicles, allowing for potential regrowth, which is a characteristic feature of this type of alopecia. Genetic predisposition plays a significant role in the development of alopecia areata. Individuals with a family history of autoimmune diseases are at a higher risk. Strategic product launches at regular intervals further enhance the market share of the alopecia areata segment; for instance, in June 2023, Pfizer Inc. announced that the United States Food and Drug Administration has approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. It is the first and only treatment approved by the FDA for adolescents (12 years and above) with severe alopecia areata. LITFULO is a kinase inhibitor that inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma family of kinases.

North America Dominates Alopecia Market

North America is anticipated to emerge as the dominant region in the global alopecia market, securing a substantial market share. The region boasts a sophisticated healthcare system that provides seamless diagnosis and treatment of alopecia. Patients have access to a wide range of treatment options, including advanced therapies and personalized medicine. There is heightened awareness among healthcare professionals and the public about alopecia and available treatment options. The relatively high healthcare expenditure per capita in North America facilitates increased spending on alopecia treatment. This allows patients to access a wide range of treatment options, contributing to the region's dominant market position. As the prevalence of alopecia continues to rise and new treatment options emerge coupled with USFDA approvals, North America is poised to maintain its dominance in the coming years. In July 2024, Sun Pharmaceutical Industries Limited received USFDA approval for LEQSELVI (deuruxolitinib) used for treating an autoimmune disorder in adults. LEQSELVI is a new, twice-daily oral Janus Kinase (JAK) inhibitor that disrupts the pathways involved in hair loss.

Future Market Scenario (2024-2031F)

Rising awareness among common people about alopecia is anticipated to drive the global alopecia market in the future. Several organizations across the globe are working in favor of alopecia awareness and advocacy. Some of these organizations include the National Alopecia Areata Foundation, Alopecia UK, Pfizer Inc., Canadian Alopecia Areata Foundation, Scarring Alopecia Foundation, American Hair Loss Association, Australia Alopecia Areata Foundation, and many more.

In 1986, the National Alopecia Areata Foundation declared September Alopecia Awareness Month, and since then, several awareness campaigns, marches, donation drives, and other initiatives to enhance awareness about alopecia and its treatment options are observed every year. Such initiatives from stakeholder organizations are anticipated to improve the diagnosis rate and thus drive the future demand for alopecia treatment.

Key Players Landscape and Outlook

The alopecia market comprises several market players ranging from small-cap to large-cap companies. Although the greater share of the market is covered by giants like Eli Lilly and Company and Sun Pharmaceutical Industries Limited, the smaller players, startups, are mainly invested in targeted therapies and treatment development, including medical devices like laser caps. The trend of acquisitions and collaborative business has been observed in the market in recent times.

For instance, in September 2024, Eli Lilly and Company, in collaboration with EVA Pharma (a subsidiary of Armanious Group), announced an agreement to increase access to baricitinib for an estimated 20,000 individuals across 49 low- to middle-income countries in Africa by 2030. Baricitinib, discovered by Incyte Corporation and licensed to Lilly, is used in the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19. This collaboration is part of the Lilly 30x30 initiative, which aims to enhance access to quality healthcare for 30 million people living in resource-limited settings annually by 2030.

In March 2023, Sun Pharmaceutical Industries Limited completed its acquisition of Concert Pharmaceuticals, Inc. This company is a late-stage clinical biopharmaceutical company developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor for potentially treating adult patients with moderate to severe alopecia areata.